OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - ELI LILLY & CO | Market Closed - Boerse Frankfurt Warrants 15:49:37 2024-05-31 EDT | ||
| 56.26 EUR | +0.23% |
|
| 1 month | +4.04% | ||
| 3 months | +8.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 55.88 | -0.45% |
| 24-05-30 | 56.13 | +0.12% |
| 24-05-29 | 56.06 | +1.78% |
| 24-05-28 | 55.08 | -1.29% |
| 24-05-27 | 55.8 | +0.43% |
Real-time Boerse Frankfurt Warrants
Last update May 31, 2024 at 03:49 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SD9V47 |
| ISIN | DE000SD9V474 |
| Date issued | 2021-01-11 |
| Strike | 205.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 56.6 € |
|---|---|
| Lowest since issue | 0.81 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Certificates
- Certificat
